1.09HKD
866.91 MHKD
2.86 BHKD
317.64 M
About CONSUN PHARMACEUTICAL GRP LIMITED
Sector
CEO
Meng An
Headquarters
Guangzhou
Website
Founded
1997
ISIN
KYG2524A1031
FIGI
BBG005P67Y41
Consun Pharmaceutical Group Ltd. is an investment holding company, which engages in the manufacturing and sales of pharmaceutical products. It operates through the Consun Pharmaceutical and Yulin Pharmaceutical segments. The Consun Pharmaceutical segment manufactures and sells modern Chinese medicines and medical contrast medium. The Yulin Pharmaceutical segment retails traditional Chinese medicines. The company was founded by Qian Li in 1997 and is headquartered in Guangzhou, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 1681 is 5.40 HKD — it has decreased by 2.70% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange CONSUN PHARMACEUTICAL GRP LIMITED stocks are traded under the ticker 1681.
CONSUN PHARMACEUTICAL GRP LIMITED is going to release the next earnings report on Aug 22, 2024. Keep track of upcoming events with our Earnings Calendar.
1681 stock is 3.74% volatile and has beta coefficient of 0.42. Check out the list of the most volatile stocks — is CONSUN PHARMACEUTICAL GRP LIMITED there?
One year price forecast for CONSUN PHARMACEUTICAL GRP LIMITED has a max estimate of 8.67 HKD and a min estimate of 7.07 HKD.
Yes, you can track CONSUN PHARMACEUTICAL GRP LIMITED financials in yearly and quarterly reports right on TradingView.
1681 stock has fallen by 4.26% compared to the previous week, the month change is a 8.63% fall, over the last year CONSUN PHARMACEUTICAL GRP LIMITED has showed a 8.00% increase.
1681 net income for the last quarter is 471.72 M HKD, while the quarter before that showed 393.45 M HKD of net income which accounts for 19.89% change. Track more CONSUN PHARMACEUTICAL GRP LIMITED financial stats to get the full picture.
Today CONSUN PHARMACEUTICAL GRP LIMITED has the market capitalization of 4.40 B, it has decreased by 1.92% over the last week.
CONSUN PHARMACEUTICAL GRP LIMITED dividend yield was 9.43% in 2023, and payout ratio reached 41.05%. The year before the numbers were 7.41% and 29.87% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 1681 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CONSUN PHARMACEUTICAL GRP LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CONSUN PHARMACEUTICAL GRP LIMITED technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CONSUN PHARMACEUTICAL GRP LIMITED stock shows the buy signal. See more of CONSUN PHARMACEUTICAL GRP LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CONSUN PHARMACEUTICAL GRP LIMITED future price: according to them, 1681 price has a max estimate of 8.67 HKD and a min estimate of 7.07 HKD. Read a more detailed CONSUN PHARMACEUTICAL GRP LIMITED forecast: see what analysts think of CONSUN PHARMACEUTICAL GRP LIMITED and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CONSUN PHARMACEUTICAL GRP LIMITED EBITDA is 931.80 M HKD, and current EBITDA margin is 32.59%. See more stats in CONSUN PHARMACEUTICAL GRP LIMITED financial statements.